Results 11 to 20 of about 70,073 (274)

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2019
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial ...
Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R, for the ARAMIS Investigators, Aglietta, Massimo, Damiano, Rocco, Facchini, Gaetano, Gasparro, Donatello, Mucciardi, Giuseppe, Natoli, Clara, Sabbatini, Roberto, Scagliotti, Giorgio, Schepisi, Giuseppe, Serretta ,Vincenzo   +24 more
openaire   +4 more sources

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

New England Journal of Medicine, 2021
BACKGROUND Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer.
O. Sartor, J. D. de Bono, K. Chi, K. Fizazi, K. Herrmann, K. Rahbar, S. Tagawa, L. Nordquist, N. Vaishampayan, G. El-Haddad, Chandler Park, T. Beer, A. Armour, Wendy J Pérez-Contreras, M. Desilvio, E. Kpamegan, G. Gericke, R. Messmann, M. Morris, B. Krause   +19 more
semanticscholar   +1 more source

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology, 2023
PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly ...
K. Chi, D. Rathkopf, M. Smith, E. Efstathiou, G. Attard, D. Olmos, Ji Youl Lee, E. Small, A. J. Pereira de Santana Gomes, G. Roubaud, M. Saad, B. Żurawski, V. Sakalo, G. Mason, P. Francis, George C. Wang, Daphne Wu, B. Diorio, A. Lopez-Gitlitz, S. Sandhu   +19 more
semanticscholar   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer

Pharmaceutics, 2021
Heat shock protein 27 (Hsp27) has an established role in tumor progression and chemo-resistance of castration-resistant prostate cancer (CRPC). Hsp27 protects eukaryotic translation initiation factor 4E (eIF4E) from degradation, thereby maintaining ...
Hajer Ziouziou, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, Palma Rocchi   +13 more
doaj   +1 more source

Current therapy and drug resistance in metastatic castration-resistant prostate cancer.

Drug resistance updates, 2023
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for
Maoping Cai, Xian-lu Song, Xinan Li, Ming-Kun Chen, Jiading Guo, Dong Yang, Zhanghui Chen, Shan-Chao Zhao   +7 more
semanticscholar   +1 more source

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Frontiers in Bioengineering and Biotechnology, 2022
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation.
Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen   +7 more
doaj   +1 more source

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source